{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-030087","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.160324+00:00","generated_at":"2026-06-19T19:29:11.789345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MEI Pharma posts net income of $10.3M; discontinues zandelisib development outside Japan","bullets":["Net income of $10.3M ($0.08 per share) vs net loss of $12.2M in prior-year quarter.","Revenue surged to $32.7M (up from $11.8M) driven by updated cost estimates on Kyowa Kirin license.","Cash and investments $124.2M with no debt; cash used in operations $14.3M.","Discontinued global development of zandelisib outside Japan; initiated workforce reduction.","Pipeline narrowed to voruciclib (Phase 1b with venetoclax) and ME-344 (Phase 1 in colorectal cancer)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-030087","json":"https://secwatch.observer/filing/0001193125-23-030087.json","markdown":"https://secwatch.observer/filing/0001193125-23-030087.md","text":"https://secwatch.observer/filing/0001193125-23-030087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523030087/0001193125-23-030087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523030087/d387877d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T19:29:11.789345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"250e3d6bdcf5b8167fa57f401e62a01b38399c43","claim":"Lite Strategy, Inc. reported second quarter ended December 31, 2022 results: revenue $32.7 million, net income $10.3 million, EPS $0.08 per share.","evidence_excerpt":"• MEI recognized revenue of $32.7 million for the quarter ended December 31, 2022, compared to $11.8 million for the quarter ended December 31, 2021. As a result of the discontinuation of the zandelisib program, we updated our estimated costs to complete each development performance obligation under the license agreement with Kyowa Kirin. This resulted in a higher progress towards completion and revenue for performance obligations that will not commence. • Net income was $10.3 million, or $0.08 per share, for the quarter ended December 31, 2022, compared to net loss of $12.2 million, or $0.10 per share for the quarter ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523030087/0001193125-23-030087-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended December 31, 2022"},{"label":"Revenue","value":"$32.7 million"},{"label":"Net income","value":"$10.3 million"},{"label":"EPS","value":"$0.08 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}